- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00543517
Study A - MK0767 Monotherapy Study
February 9, 2015 updated by: Merck Sharp & Dohme LLC
The purpose of this study is to test if MK0767 lowers blood glucose after 20 weeks compared to placebo.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Study Overview
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Type 2 Diabetes
- Non-pregnant females and patients who agree not to become pregnant during the study
Exclusion Criteria:
- Patients with Type 1 Diabetes
- Patients who have been treated with insulin or other antihyperglycemic agents
- Patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, HIV positive, history hematologic disorders or neoplastic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
November 1, 2003
Study Completion (Actual)
November 1, 2003
Study Registration Dates
First Submitted
October 5, 2007
First Submitted That Met QC Criteria
October 12, 2007
First Posted (Estimate)
October 15, 2007
Study Record Updates
Last Update Posted (Estimate)
February 10, 2015
Last Update Submitted That Met QC Criteria
February 9, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0767-023
- 2007_638
- MK-0767-023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on MK0767
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDyslipidemia | Diabetes Mellitus, Type II
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedMetabolic X Syndrome Dyslipidemia